Table 2.

Individual effect of baseline TBiL concentrations (T1–T2 vs T3) and cigarette smoking (never, ever) on primary and secondary outcomes

Outcomes	Events/N (%)	OR (95% CI)
		Unadjusted	Adjusteda
Progression of CKD
TBiL (μmol/L)
Per SD		0.84 (0.74–0.95)	0.80 (0.70–0.92)
Categories
T1–T2 (<11.7)	211/8407 (2.5)	Ref (1.00)	Ref (1.00)
T3 (≥11.7)	83/4226 (2.0)	0.78 (0.60–1.01)	0.72 (0.55–0.95)
Smoking status
Never	194/8972 (2.2)	Ref (1.00)	Ref (1.00)
Ever	100/3657 (2.7)	1.27 (1.00–1.62)	1.11 (0.78–1.57)
Rapid decline in eGFR
TBiL (μmol/L)
Per SD		0.84 (0.78–0.91)	0.86 (0.79–0.94)
Categories
T1–T2 (<11.7)	577/8406 (6.9)	Ref (1.00)	Ref (1.00)
T3 (≥11.7)	226/4226 (5.3)	0.77 (0.65–0.90)	0.80 (0.68–0.95)
Smoking status
Never	559/8971 (6.2)	Ref (1.00)	Ref (1.00)
Ever	243/3657 (6.6)	1.07 (0.92–1.25)	1.29 (1.02–1.63)
Decline in eGFR, % per year
TBiL (μmol/L)
Per SD		−0.18 (−0.24, −0.12)c	−0.13 (−0.19, −0.06)c
Categories
T1–T2 (<11.7)	1.47 (3.38)b	Ref (0.00)	Ref (0.00)
T3 (≥11.7)	1.16 (3.37)b	−0.31 (−0.43, −0.18)c	−0.21 (−0.34, −0.08)c
Smoking status
Never	1.35 (3.33)b	Ref (0.00)	Ref (0.00)
Ever	1.40 (3.49)b	0.04 (−0.09, 0.17)c	0.16 (−0.02, 0.34)c

Notes:

^aAdjusted for age, sex, treatment group, systolic blood pressure, body mass index, smoking status, alcohol intake, eGFR, proteinuria, serum glucose, total cholesterol, alanine aminotransferase, aspartate transaminase at baseline, and time-averaged systolic blood pressure during treatment if not as an independent variable.

^bMean (SD).

^cValues are regression coefficients (95% CI).

Abbreviations: T1, tertile 1; T2, tertile 2; T3, tertile 3; TBiL, total bilirubin; SD, standard deviation; CKD, chronic kidney disease; eGFR, estimated glomerular filtration rate; OR, odds ratio; CI, confidence interval; Ref, reference.